Harbor Advisors LLC Makes New Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Harbor Advisors LLC acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 4th quarter, Holdings Channel.com reports. The fund acquired 2,500 shares of the medical equipment provider’s stock, valued at approximately $224,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. State of New Jersey Common Pension Fund D boosted its holdings in shares of Lantheus by 0.4% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock valued at $2,364,000 after purchasing an additional 115 shares during the last quarter. Bleakley Financial Group LLC boosted its holdings in shares of Lantheus by 6.1% during the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock valued at $200,000 after purchasing an additional 129 shares during the last quarter. Avantax Advisory Services Inc. boosted its holdings in shares of Lantheus by 5.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider’s stock valued at $213,000 after purchasing an additional 132 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares during the last quarter. Finally, Aurora Investment Counsel boosted its holdings in shares of Lantheus by 0.8% during the 4th quarter. Aurora Investment Counsel now owns 19,200 shares of the medical equipment provider’s stock valued at $1,718,000 after purchasing an additional 146 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on LNTH. The Goldman Sachs Group began coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. Truist Financial increased their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, February 27th. B. Riley lowered their price target on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a report on Friday. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and an average target price of $129.43.

Insider Buying and Selling

In related news, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 64,109 shares of company stock valued at $6,110,806 in the last ninety days. 1.50% of the stock is owned by company insiders.

Lantheus Trading Down 1.2 %

Shares of NASDAQ:LNTH opened at $97.71 on Friday. Lantheus Holdings, Inc. has a 12 month low of $57.92 and a 12 month high of $126.89. The company has a market cap of $6.69 billion, a price-to-earnings ratio of 16.26 and a beta of 0.38. The company has a 50-day moving average price of $92.67 and a 200 day moving average price of $96.58.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. As a group, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.